Physician profile
Karla B Cepeda
NPI 1518057702
$1,505.96
in general payments reported to CMS, 2019-2025
17 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $262 · 2021: $13.40 · 2022: $191 · 2023: $36.53 · 2024: $138 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.89 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.81 | 2020-2025 | Airsupra |
| Edwards Lifesciences Corporation | $226.48 | 2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $198.50 | 2021-2025 | Qulipta |
| Amgen INC. | $161.96 | 2024-2025 | Evenity, Repatha, Otezla |
| Tactile Systems Technology INC | $139.22 | 2020 | |
| Lilly USA, LLC | $91.03 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $73.78 | 2025 | |
| Novo Nordisk INC | $57.76 | 2025 | Wegovy |
| Boston Scientific Corporation | $52.65 | 2025 | Watchman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.25 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $47.17 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $34.69 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
| Inspire Medical Systems, INC. | $27.56 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $22.96 | 2025 | |
| Dexcom, INC. | $22.43 | 2025 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.63 | 2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $15.08 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Cepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.